Black Diamond Therapeutics (BDTX) shares were climbing Tuesday, up 3.51% in premarket trading to $2.36, after the company shared some encouraging news from its cancer drug pipeline.

The clinical-stage oncology company recently reported Phase 2 data for silevertinib, its lead candidate, in patients with frontline non-small cell lung cancer (NSCLC) who have EGFR non-classical mutations. The results, the company says, support silevertinib's potential as a practice-changing treatment, with promising preliminary progression-free survival data. Those findings are set to be presented at the ASCO Annual Meeting on May 30, 2026.

Earlier this month, Black Diamond reported first-quarter earnings that beat Wall Street expectations. The company posted a loss of $0.16 per share, better than the $0.18 loss analysts had forecast. Research and development expenses fell to $7 million from $10.5 million a year ago, largely due to progress in the Phase 2 silevertinib trial and the outlicensing of BDTX-4933 as the company sharpens its focus on silevertinib. As of March 31, the company had $118.3 million in cash, cash equivalents, and investments, which management says should fund operations into the second half of 2028.

So what does the technical picture look like for BDTX? At $2.36, the stock is trading 16.2% below its 20-day simple moving average (SMA) of $2.84 and 9.7% below its 50-day SMA of $2.63. Over the past 12 months, the stock is up 11.22%, showing some resilience despite recent volatility. The moving averages tell a mixed story: the 20-day SMA is above the 50-day SMA, which is a bullish short-term signal. But the 50-day SMA is below the 200-day SMA, forming a death cross that suggests longer-term bearish sentiment. The MACD is currently below its signal line, indicating that momentum is fading—something traders might want to keep an eye on.

Black Diamond Therapeutics is a clinical-stage oncology company developing what it calls MasterKey therapies that target families of oncogenic mutations. Its foundation is built on a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its lead program, silevertinib (formerly BDTX-1535), is in a Phase 2 trial for EGFR mutant NSCLC.

Analysts are broadly bullish on the stock. The average price target is $11.00, with a Buy rating. Recent analyst moves include BTIG raising its forecast to $11.00 on April 29, Wedbush boosting its target to $14.00 on March 17, and Piper Sandler lowering its target to $8.00 on January 16—though still maintaining an Overweight rating.

With the ASCO presentation just days away, all eyes will be on silevertinib's data and whether it can live up to the hype.